AstraZeneca announces Calquence approved in Japan to treat CLL
The Fly

AstraZeneca announces Calquence approved in Japan to treat CLL

AstraZeneca’s Calquence, a selective Bruton’s tyrosine kinase, or BTK, inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naive chronic lymphocytic leukaemia, or CLL. Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on AZN:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App